49,584 Shares in Cassava Sciences, Inc. (NASDAQ:SAVA) Purchased by Sherbrooke Park Advisers LLC

Sherbrooke Park Advisers LLC acquired a new position in Cassava Sciences, Inc. (NASDAQ:SAVA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 49,584 shares of the company’s stock, valued at approximately $117,000. Sherbrooke Park Advisers LLC owned about 0.10% of Cassava Sciences at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Sequoia Financial Advisors LLC purchased a new position in shares of Cassava Sciences in the fourth quarter worth about $26,000. CANADA LIFE ASSURANCE Co lifted its stake in shares of Cassava Sciences by 198.4% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 11,380 shares of the company’s stock worth $27,000 after buying an additional 7,566 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in shares of Cassava Sciences in the fourth quarter worth about $27,000. Johnson Investment Counsel Inc. increased its stake in shares of Cassava Sciences by 71.4% in the 4th quarter. Johnson Investment Counsel Inc. now owns 12,000 shares of the company’s stock worth $28,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Catalina Capital Group LLC acquired a new stake in shares of Cassava Sciences in the 4th quarter worth $32,000. 38.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 target price on shares of Cassava Sciences in a research note on Tuesday, March 25th.

Cassava Sciences Stock Down 8.5%

Shares of SAVA opened at $2.05 on Thursday. Cassava Sciences, Inc. has a 52-week low of $1.15 and a 52-week high of $42.20. The company has a market capitalization of $99.03 million, a PE ratio of -1.49 and a beta of -2.31. The stock has a fifty day simple moving average of $1.73 and a two-hundred day simple moving average of $4.85.

Cassava Sciences (NASDAQ:SAVA) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.48) earnings per share for the quarter. As a group, equities analysts anticipate that Cassava Sciences, Inc. will post -3.97 earnings per share for the current fiscal year.

Cassava Sciences Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.